Compare COUR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | ABCL |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 1.1B |
| IPO Year | 2021 | 2020 |
| Metric | COUR | ABCL |
|---|---|---|
| Price | $5.38 | $4.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $10.53 | $8.40 |
| AVG Volume (30 Days) | 6.3M | ★ 8.2M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.22 | 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $757,500,000.00 | $75,128,000.00 |
| Revenue This Year | $9.43 | N/A |
| Revenue Next Year | $6.40 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.04 | ★ 160.56 |
| 52 Week Low | $5.00 | $1.94 |
| 52 Week High | $13.56 | $6.52 |
| Indicator | COUR | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 44.33 |
| Support Level | $5.11 | $3.93 |
| Resistance Level | $6.41 | $4.84 |
| Average True Range (ATR) | 0.31 | 0.38 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 25.80 | 11.88 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.